Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study
- 844 Downloads
Sepsis is the most common cause of death in medical intensive care units (ICU). If sepsis progresses to refractory septic shock, mortality may reach 90–100% despite optimum current therapy. Extracorporeal cytokine adsorption in addition to regular therapy was studied prospectively in refractory septic shock patients on a medical ICU. Refractory shock was defined as increasing vasopressor dose required to maintain mean arterial blood pressure above 65 mmHg or increasing lactate levels despite protocol-guided shock therapy for 6 h. We analysed noradrenaline requirements after 6 and 12 h (primary endpoint), lactate clearance after 6 and 12 h, SOFA-scores in the first days and achievement of shock reversal (i.e., normalization of lactate concentrations and sustained discontinuation of vasopressors; secondary endpoints). Twenty consecutive patients with refractory septic shock were included; CytoSorb® treatment was started after 7.8 ± 3.7 h of shock therapy. Following the initiation of adsorption therapy, noradrenaline dose could be significantly reduced after 6 (−0.4 µg/kg/min; p = 0.03) and 12 h (−0.6 µg/kg/min; p = 0.001). Lactate clearance improved significantly. SOFA-scores on day 0, 1 and 2 remained unchanged. Shock reversal was achieved in 13 (65%) patients; 28-day survival was 45%. In severe septic shock unresponsive to standard treatment, haemodynamic stabilization was achieved using cytokine adsorption therapy, resulting in shock reversal in two-thirds of these patients. The study was registered in the German Register for Clinical Trials (DRKS) No. 00005149.
KeywordsSeptic shock therapy Refractory septic shock Interleukin 6 Blood purification CytoSorb®
We are indebted to the nursing staff of our intensive care unit and the staff of the dialysis department for their excellent work. We thank Mr. Sebastian Maletzki for his help with the data collection and data presentation.
Compliance with ethical standards
Ethics approval and consent to participate
This study was approved by the institutional ethics committee of the Ernst Moritz Arndt University Greifswald (No. BB 048/13). Written informed consent was obtained from patients or their legal representatives.
Conflict of interest
CytoSorbents Europe supplied the hemadsorption cartridges used in this study free of charge. SF has received lecture honoraria, AN has received lecture honoraria and travel reimbursements from CytoSorbents Europe. SSS, SG and SBF declare no conflicts of interest.
- 15.Schädler D, Porzelius C, Jörres A, Marx G, Meier-Hellmann A, Putensen C, Quintel M, Spies C, Engel C, Weiler N, Kuhlmann M. A multicenter randomized controlled study of an extracorporeal cytokine hemoadsorption device in septic patients. eposter Crit Care; 2013.Google Scholar
- 24.Bayer O, Reinhart K, Kohl M, Kabisch B, Marshall J, Sakr Y, et al. Effects of fluid resuscitation with synthetic colloids or crystalloids alone on shock reversal, fluid balance, and patient outcomes in patients with severe sepsis: a prospective sequential analysis. Crit Care Med. 2012;40:2543–51.CrossRefPubMedGoogle Scholar
- 25.Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26:1793–800.CrossRefPubMedGoogle Scholar